智通财经APP讯，四环医药(00460)发布公告，于2025年10月15日，受托人已就股份奖励计划于市场上购 买合共925.5万股公司股份。 ...

四环医药(00460)发布公告，于2025年10月15日，受托人已就股份奖励计划于市场上购买合共925.5万股 公司股份。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 Sihuan Pharmaceutical Holdings Group Ltd. 四環醫藥控股集團有限公司 （於百慕達註冊成立的有限公司） （股份代號：0460） 自願公告 根據股份獎勵計劃購買股份 此 乃 四 環 醫 藥 控 股 集 團 有 限 公 司（「本公司」或「四環醫藥」，連 同 其 附 屬 公 司， 統 稱 為「本集團」）作 出 的 自 願 公 告。 兹 提 述 本 公 司 日 期 為 二 零 二 二 年 十 月 二 十 六 日 的 公 告（「該公告」），內 容 有 關 （其 中 包 括）本 公 司 採 納 二 零 二 二 年 股 份 獎 勵 計 劃（「股份獎勵計劃」）。除 文 義 另 有 所 指 外，本 公 告 所 用 詞 彙 與 該 公 告 所 界 定 者 具 有 相 同 涵 義。於 二 零 二 五 年 十 月 十 五 日，受 託 ...

格隆汇10月15日丨四环医药(00460.HK)宣布，关建议分拆及公司附属公司轩竹生物于联交所主板独立上 市。于全球发售完成后，分拆公司于2025年10月15日在联交所主板上市，而分拆公司H股于2025年10月 15日上午九时正开始于联交所主板买卖。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 本 公 告 僅 供 參 考，並 不 構 成 收 購、購 買 或 認 購 任 何 證 券 的 邀 請 或 要 約。 董 事 會 欣 然 宣 佈，於 全 球 發 售 完 成 後，分 拆 公 司 於 二 零 二 五 年 十 月 十 五 日 在 聯 交 所 主 板 上 市，而 分 拆 公 司H股於二零二五年十月十五日上午九時正開始 於 聯 交 所 主 板 買 賣。 緒 言 本公告並不構成在美國境內或在任何其他司法管轄區提呈出售要約或招攬購 買 任 何 證 券 的 要 約，倘 未 根 據 任 何 該 等 司 法 管 轄 區 的 證 券 法 辦 理 登 記 或 未 獲 批 准 而 於 上 述 地 區 進 行 上 述 要 約、招 攬 或 出 售 即 屬 違 法。本 公 告 所 述 的 證 券 將 不會根據經修訂的1933年 美 國 證 券 法（「證券法」）登 記 ...

Core Viewpoint - The ongoing trend of biopharmaceutical companies listing in Hong Kong is driven by the need for capital and the advantages of Hong Kong's research infrastructure and regulatory environment, which support mainland companies in entering international markets [2][8]. Group 1: IPO Activity - Over 12 biopharmaceutical companies, including Anhui Huaheng Bio, Betta Pharmaceuticals, and Xuan Bamboo Bio, have submitted IPO applications in Hong Kong since mid-September [1]. - Xuan Bamboo Bio's stock opened at HKD 29.46, a 153.97% increase from its issue price of HKD 11.6, with a market capitalization exceeding HKD 15 billion [1]. Group 2: Financial Performance - Xuan Bamboo Bio reported revenues of HKD 2.9 million, HKD 30.09 million, and HKD 17.89 million for 2023, 2024, and the first half of 2025, respectively, while experiencing losses of HKD 300 million, HKD 556 million, and HKD 111 million during the same periods [6]. - The company has a cash balance of HKD 8.558 million as of mid-2025, indicating a need for ongoing funding to support its operations and R&D [6]. Group 3: Product Pipeline and Market Competition - Xuan Bamboo Bio has three core products approved for market, including KBP-3571, a proton pump inhibitor (PPI) for treating digestive diseases, which has become a significant revenue source [3][4]. - The PPI market in China is competitive, with major players like Rabeprazole and Esomeprazole dominating, and Xuan Bamboo Bio faces challenges from generic competitors as patents expire [5][6]. - The company is expanding the indications for KBP-3571 to include reflux esophagitis, with clinical trials currently in Phase III [5]. Group 4: Industry Insights - The capital market is increasingly recognizing the value of innovative biopharmaceutical companies, emphasizing the importance of balancing cash flow with R&D pipeline development [2][8]. - Listing in Hong Kong allows companies to attract global capital and accelerate drug development and market promotion, but they must demonstrate tangible results to maintain investor interest [8].

Core Viewpoint - The ongoing trend of biopharmaceutical companies going public in Hong Kong is driven by the need for funding and the advantages of Hong Kong's research infrastructure and regulatory environment [2][3] Group 1: IPO Activity - Over 12 biopharmaceutical companies have submitted IPO applications in Hong Kong since mid-September, covering areas such as innovative drug development and vaccines [2] - Xuan Zhu Biotech, which completed its IPO application in June, opened at HKD 29.46 per share, a 153.97% increase from its issue price of HKD 11.6, with a market capitalization exceeding HKD 15 billion [2] - The company plans to use 45% of the raised funds for core product R&D, 14% for key product development, and 20% for enhancing commercialization and marketing capabilities [2] Group 2: Market Dynamics - The collaboration between mainland Chinese pharmaceutical companies and Hong Kong is expected to deepen in product R&D, market strategy, and capital operations [3] - The capital market is returning to the essence of value recognition for biopharmaceutical assets, with innovative companies gaining continuous attention [3] Group 3: Competitive Landscape - Xuan Zhu Biotech has three core products approved for market, including KBP-3571, which has become a major revenue source [4] - The PPI market in China has remained above CNY 10 billion from 2018 to 2024, but competition is intensifying due to the inclusion of several common PPIs in centralized procurement [5] - Xuan Zhu Biotech is expanding the indications for KBP-3571 to include reflux esophagitis, which is currently in Phase III clinical trials [6] Group 4: Financial Performance - Xuan Zhu Biotech is experiencing revenue growth but also increasing losses, with revenues of CNY 2.9 million and CNY 30.09 million in 2023 and 2024, respectively, and total losses of CNY 3 billion and CNY 5.56 billion [7] - The company has over ten drug assets in development, with a significant focus on R&D spending, which was CNY 3.84 billion, CNY 2.85 billion, and CNY 1.06 billion for 2023, 2024, and the first half of 2025, respectively [8] Group 5: Future Outlook - The biopharmaceutical industry is characterized by high investment, long cycles, and high risks, leading to a continuous need for funding [7] - Companies must demonstrate tangible results in clinical value or commercial revenue to attract capital and resources in a competitive market [9]

Core Viewpoint - Xuan Zhu Bio-B (2575.HK), spun off from Sihuan Pharmaceutical, saw a significant first-day listing increase of 153.97%, opening at HKD 29.46, compared to its IPO pricing of HKD 11.6 [1] Company Overview - Xuan Zhu Bio is an innovation-driven biopharmaceutical company in China, focusing on improving patient health and life through a deep understanding of the Chinese pharmaceutical industry and its unique clinical needs [1] - Since Sihuan Pharmaceutical acquired a majority stake in Shandong Xuan Zhu in 2008, the company has established a comprehensive internal R&D platform to support a diverse and balanced pipeline [1] Product Pipeline - As of the last feasible date, Xuan Zhu Bio has over ten drug assets actively in development, targeting diseases such as digestive system disorders, tumors, and non-alcoholic steatohepatitis (NASH) [1] - The pipeline includes three assets with NDA approval, one project in the NDA registration stage, one project in Phase III clinical trials, four projects in Phase I clinical trials, and five projects that have received IND approval [1] IPO Performance - The public offering was oversubscribed by 4,908.33 times, while the international placement was oversubscribed by 10.15 times [1] - The stock's opening price of HKD 29.46 represents a significant increase from the IPO price, indicating strong market interest and investor confidence [2]

Market Performance - The Hang Seng Healthcare Index decreased by 2.74% as of October 14, 2025, with mixed performance among constituent stocks [1] - The Hang Seng Healthcare ETF (513060) fell by 1.74%, with a latest price of 0.68 CNY, but has seen an 18.15% increase over the past three months [1] - The Hong Kong Stock Connect Innovative Drug Selection Index dropped by 3.58%, with the latest price of the corresponding ETF (520690) at 0.94 CNY, reflecting a decline of 2.28% [2] - The CSI Pharmaceutical 50 Index decreased by 1.24%, with the latest price of the Pharmaceutical 50 ETF (159838) at 0.63 CNY, showing an 11.34% increase over the past three months [2] Liquidity and Trading Activity - The Hang Seng Healthcare ETF had a turnover of 12.72% and a trading volume of 884 million CNY, indicating active market participation [1] - The Hong Kong Innovative Drug Selection ETF recorded a turnover of 21.74% with a trading volume of 90.47 million CNY [2] - The Pharmaceutical 50 ETF had a turnover of 1.01% and a trading volume of 1.66 million CNY, with an average daily trading volume of 6.33 million CNY over the past week [3] Regulatory and Market Developments - The National Healthcare Security Administration issued a notice to strengthen the regulation of retail pharmacies, targeting "dual pricing" practices, which may accelerate compliance in the pharmacy sector [3] - Boteng Co., Ltd. expects a revenue growth of 17%-21% year-on-year for the first three quarters, indicating a recovery in the CDMO sector driven by global client pipeline expansion [3] - Four Seasons Pharmaceutical has acquired a stake in Swiss Suisselle SA, gaining exclusive rights to the CELLBOOSTER® product, enhancing its international brand collaboration and product matrix [3] Institutional Insights - The overall signal for the pharmaceutical sector is neutral, with regulatory pressures on retail pharmacies but resilience in CDMO and medical aesthetics sectors [4] - Short-term focus is on the sustainability of performance recovery for companies like Boteng, while mid-term attention is on international collaborations in medical aesthetics and growth in the innovative drug outsourcing industry [4] Fund Flows and Performance - The Hang Seng Healthcare ETF saw a net inflow of 12.05 million CNY, accumulating 177 million CNY over the past 15 trading days [6] - The Hong Kong Innovative Drug Selection ETF reached a record high of 434 million shares, with a net inflow of 2.89 million CNY recently [7] - The CSI Pharmaceutical 50 Index includes major companies like WuXi AppTec and Hengrui Medicine, with the top ten stocks accounting for 59.46% of the index [8]

Policy Developments - Shanghai has announced a reduction in prices for certain medical services, including continuous dynamic blood glucose monitoring, effective from October 15, 2025 [2] Drug and Device Approvals - Humanwell Healthcare's Dapoxetine Hydrochloride Tablets received a drug registration certificate, with projected national sales of approximately 1.1 billion yuan for 2024 [4] - Anglikon has received a drug registration certificate for its Amlodipine Besylate Tablets, aimed at treating primary hypertension in adults [5] - David Medical's subsidiary has obtained a medical device registration for a portable electronic endoscope image processor, enhancing endoscopic diagnostics [6] - The National Medical Products Administration approved the listing of Momelotinib Tablets, providing a new treatment option for moderate to severe plaque psoriasis [7] - Hengrui Medicine's subsidiary received clinical trial approval for SHR-1905 injection, a monoclonal antibody targeting inflammatory cytokines, with a similar product projected to generate approximately 1.22 billion USD in global sales for 2024 [8] - Lingbei's investigational drug Bexicaserin has been recognized as a breakthrough therapy for developmental epileptic encephalopathy-related seizures [15] Capital Market Activities - Four Seasons Pharmaceutical's trustee purchased a total of 10 million shares under a share incentive plan at an average price of approximately 1.619 HKD per share [10] - Jiuan Medical plans to repurchase shares worth no less than 300 million yuan and no more than 600 million yuan, with a maximum repurchase price of 53.5 yuan per share [11] Industry Developments - The Shanghai High-end Medical Device Cluster was officially launched, aiming to achieve over 500 new domestic Class III medical device registrations and over 100 overseas approvals by 2027 [13] - Boehringer Ingelheim announced the local production plan for its diabetes drug Otonil, with an investment of over 5 billion yuan in R&D over the next five years [14] Financial Disclosures - Boteng Co. expects a net profit of 73.2 million to 88.2 million yuan for the first three quarters of 2025, marking a turnaround from losses, with revenue growth of 17% to 21% [17] - Saintno Bio anticipates a net profit increase of 100.53% to 145.10% for the first three quarters of 2025, driven by stable business growth and increased demand for peptide raw materials [19]